The objective of the study was to assess the cost of multiple sclerosis (MS) patients in Argentina categorized by disease severity using a societal perspective. Method: Cross-sectional study including MS patients from 21 MS centers in 12 cities of Argentina. Patients were stratified by disease severity using the expanded disability status scale (EDSS) (group 1 with EDSS score between 0 and 3; group 2 with EDSS .3 and ,7; group 3 with EDSS $7). Direct and indirect costs were analyzed for the second quarter of 2012 from public sources and converted to US Dollars. Results: 266 patients were included. Mean annual cost per MS patient was USD 36,025 (95%CI 31,985-38,068) forts patients with an EDSS between 0-3; USD 40,705 (95%CI 37,300) for patients with EDSS .3 and ,7, and USD 50,712 (95%CI 47,825-62,104) for patients with EDSS $7. Conclusions: This is the first Argentine study evaluating the costs of MS considering disease severity.
Multiple sclerosis (MS) is the second most common cause of neurological disability in working-age population, after car accidents, having an impact on quality of life, social activities and also the environment of affected patients 1 . The course of the disease is highly variable, but it is most typically characterized by a relapsing pattern of acute exacerbations followed by periods of remission (relapsing-remitting MS [RRMS] ). However, in up to 50% of patients, this pattern evolves into a progressive course in which the clinical condition slowly deteriorates over the years (secondary progressive MS [SPMS]) 2 . Considering the natural course of this disease, the progressive physical disability carries hard economic consequences from the early loss of work capacity 3, 4 . MS patients required repeated hospitalizations during disease exacerbations and the need of assistance in daily life activities, being the socioeconomic cost of the disease high for patients, families, health care systems and society as a whole 4 . Mean total lifetime cost per patient of MS in the US was estimated to be USD 2.5 millions in 1994 5 , and some publications have addressed MS epidemiology and costs worldwide 6, 7, 8, 9, 10, 11 . Nonetheless, current knowledge of MS epidemiology and economic burden comes from North American and European studies 9, 10, 12, 13 . In Argentina, reported prevalence rates of MS range between 16 to 21 cases per 100,000 inhabitants 9, 14, 15 . Despite this information, the economic burden associated with the disease in Argentina as well as in the region of Latin America, is unknown.
In order to better understand the impact of the disease on national health systems in the region, the objective of the study was to measure the socioeconomic burden that MS imposes to the Argentine society by disease severity and to contribute detailed cost information in the country.
METHOD

Study design
The Treatment Experience, Burden and Unmet Needs in Multiple Sclerosis Study (ENCOMS) in Argentina was an adaptation of the successful experience of TRIBUNE performed in several European countries and Canada 16, 17, 18, 19, 20 , but using validated questionnaires for Argentina. The study was then a national, cross-sectional, observational and retrospective study including MS patients from 21 MS centers in 12 cities of Argentina. It was conducted to collect information on demographics, disease characteristics, disease severity, comorbidities, relapses as well as resource utilization and patient reported outcomes (PRO) associated with MS (ICD-10; G35, ICD-9; 340). Cities involved in the study were: Buenos Aires, Salta, Mendoza, Córdoba, Santa Cruz and Ushuaia. The study began in August 2011 and enrollment ended in February 2012. Site staff identified eligible patients by screening patient records, and an invitation to participate in the study was sent to patients who met the inclusion criteria (MS diagnosis 21, 22, 23 and at least 18 years old). Patients having any physical or mental condition making them ineligible to participate or were already enrolled in other clinical trial were excluded. The study protocol and questionnaire were approved by the Ethics Committee prior to the initiation of the study.
Assessments
Patients self-completed a written-questionnaire in Spanish during enrolment interview. Patients provided information on: age, sex, living arrangements, educational level, employment status, and informal caregiver(s). Disease information including year of diagnosis, year of first symptoms, type of MS, disability (captured using the self-administered Expanded Disability Status Scale (EDSS) 24 ), comorbidities (arthritis, osteoporosis, depression, anxiety, sleep disorders, hypertension and urinary tract infections/incontinence) and treatment with disease modifying drugs (DMDs) was also captured. The disability scale version used in the study was the modified and validated version that had been previously used in other cost-of-illness studies in MS 20 . Patients were asked about relapses experienced in the last 12 months, including occurrence and number of relapses, number of those requiring steroid treatment and number of days of inpatient care for relapses.
Resource utilization
Data on healthcare including inpatient and outpatient care, magnetic resonance imaging (MRI) studies performed, consultations with medical practitioners, treatment with DMDs, prescription and over-the-counter medication as well as non-medical resources used (wheelchairs), professional and informal care and patients' productivity loss (sick leave and retirement due to the disease), was collected using the questionnaire. Different recall periods were used for different resources. Hospital stays, investigations/MRIs and use of wheelchair were recorded for the previous year. A 3-month recall period was used for outpatient admissions, consultations with hospital-based or private practice physicians, use of DMDs, services such as home care and nursing, informal care by family and friends, and absences from work due to sickness. Patients were asked to report the use of co-medication and over-the-counter medication during the last month.
Costs
To obtain the cost per patient per year, resources used were first annualized assuming that the use of each resource during the recall period was representative of the patients' use during a whole year. The annual use of each resource was multiplied by its respective unit cost to get the annual cost. Second quarter 2012 unit costs were derived from public sources of Argentina including the Instituto Nacional de Estadísticas y Censos 25 (Indec), the Nomenclador Nacional 26 , drugs public price list 27 and, when necessary, costs from the Sanitary and Clinical Effectiveness Institute (IECS) cost database 28 . Unit cost in Argentine pesos was converted to US dollars using June 2012 exchange rate (USD 1=AR$ 4.46). Costs are shown in Table 1 . The cost of sick leave was calculated by multiplying the patient-reported days lost from work due to MS by the average gross salary per day. To estimate productivity losses of early retirement due to MS, the mean annual number of hours worked in 2011 in Argentina was multiplied by the gross salary 20 . Informal care was rated using productivity loss of the working caregiver, multiplied by the average gross salary. In order to asses only the hours leading to informal caregiver productivity loss, the average working hours per week were considered 19, 20 .
Statistical analysis
Patients were stratified according to disease severity using the EDSS (group 1 with EDSS between 0 and 3; group 2 with EDSS .3 and ,7; group 3 with EDSS $7) for the analysis. Use of resources was determined for each group and cost was obtained from the estimated resource utilization. Confidence intervals (95%) for costs were estimated by non-parametric bootstrapping. A non-parametric statistical test for independent samples (Wilcoxon-MannWhitney test) was used to determine whether differences between comparisons performed were statistically significant (p-value,0.05).
RESULTS
Patient characteristics
A total of 266 patients were enrolled. Mean age of patients enrolled was 42.3±10.5 years, Reported mean age at the onset of the disease was 31.6±9 years Almost 20% of patients had a university degree and 16.5% of patients were currently retired due to the disease. Most MS patients had the relapsing-remitting form of the disease (87.6%). When stratifying the sample included, 188 (70.7%) patients had an EDSS score between 0 and 3; 51 (19.2%) an EDSS .3 and ,7 and 27 (10.1%) an EDSS $7). Patients with mild disability were younger than moderate or severe MS patients (p-value=0.007). The remaining patient characteristics including comorbidities, employment status and living situation are displayed in Table 2 .
Resource utilization
The proportion of patients who received inpatient care, had medical visits and used co medications significantly increased across disability severity subgroups, being 10%, 27% and 100%, respectively, in patients with an EDSS $7, while the proportion of patients with MS-specific medication decreased from 77.1% to 51.8% in patients with EDSS between 0 and 3 and EDSS $7 respectively. Informal care was more frequently reported among patients with severe disability compared with patients with moderate and mild disability (100% vs. 61% vs. 21%, respectively). Almost 85% of patients with an EDSS $7 were retired due to MS. Other resource utilization by patients is shown in Table 3 .
Costs
The mean cost per MS patient per year stratified by disability from a societal perspective was measured and is displayed in Table 4 and Figure. The mean cost of patients significantly increased across disability severity groups, being of USD 36,025 (95% confidence interval (CI) 31,985-38,068) in patients with an EDSS between 0 and 3, USD 40,705 (95% CI37,199-46,300) in patients with EDSS .3 and ,7 In patients with EDSS $7, the cost for patients' sick leave and retirement due to MS was an important component, comprising 25.7% of total costs, while direct non-medical costs represented 21.6% of the total cost. Informal care was assessed on the base case analysis using only working caregiver productivity loss. In patients with EDSS $7, mean annual cost of informal care per patient represented 12.5% of the total annual cost per patient, while in patients with EDSS between 0 and 3 and .3 and ,7, informal care represented 0.2% and 5.6%, respectively, of total costs. In patients with EDSS between 0 and 3, most of the cost came from direct medical costs including MS-specific medication.
DISCUSSION
The robust ENCOMS study showed that MS imposes a significant economic burden on Argentine society. Mean annual cost per patient was estimated at USD 36,025 in patients with an EDSS between 0 and 3 and reached USD 50,712 in patients with EDSS $7. This economic burden increases with higher physical disability. This was accounted for by the increase in resource utilization of medical visits, informal care, professional care, sick leave as well as retirement due to MS in the sample analyzed.
Our study is consistent with previous cost-of-illness studies performed in Canada 20 and some European countries 16, 18, 29 . In Canada, Karampampa et al. also demonstrated that increased physical disability was associated with increased direct and indirect costs partially explained by a higher need for medical and non-medical care associated with disability progression 20 . In the Canadian study, the mean annual cost per patient for 2009 was estimated at CAD 30,836 for patients with mild disability (EDSS score 0-3), CAD 46,622 for patients with moderate disability (EDSS 4-6.5), and CAD 77,981 for patients with severe disability due to MS (EDSS score 7-9) 20 . The increase in the economic burden of the disease associated with the increase in physical disability, was also showed by Karampampa et al in the European health care systems such as those from Spain, France, Germany and the United Kingdom 19 . In Argentina, this is the first study designed to capture the economic burden of the disease. In Latin America, a comprehensive cost study, from a third party payer perspective and including MS patients from 3 MS centers in the country was done by Romero et al in Colombia between 2003 and 2008 30 . The study estimated direct and indirect costs according to disease progression as measured by EDSS in MS patients. The disease was classified into 4 categories according to EDSS: category 1 EDSS 0-2.5, category 2 EDSS 3-5.5, category 3 EDSS 6-7.5, and category 4 EDSS 8-9.5) and costs for each category were estimated. The study showed that the mean annual cost per patient varied across disease categories, with the highest cost in category 2 (USD 25,713) and the lowest one in category 4 (USD 10,543). The cost of DMDs accounted for 91.5% of the mean total annual cost for categories 1, 2 and 3. Indirect costs were minimal, except for category 4, where higher costs of DMDs were offset by lower use of DMDs 30 . Despite this valuable information, the study did not take into account some direct non-medical costs as well as indirect costs such as professional care, informal care, sick leave and retirement due to MS 30 . This might explain the economic burden differences observed in patients with severe disability in the study by Romero and our findings. No other studies analyzing the economic burden of the disease, stratifying by physical disability and considering direct as well as indirect costs in the Latin American region were identified.
The study has many limitations. First of all, the sample involves patients from all disability spectrums; however, the proportion of patients with severe disability was lower in relation to patients with moderate and mild disability. Therefore, a larger sample would be necessary to generalize the results. Another limitation observed in previous studies on which ENCOMS was based 19 relates to the fact that cost estimates are likely to reflect how the sample of MS patients was derived. Cost estimates would probably have been lower if the sample had included MS patients recruited from the community rather than from specialized clinics. The above could lead to the fact that many patients are receiving MS-specific treatments as well as professional and informal care in relation to total MS population in Argentina. Despite this, we tried to overcome the possibility of bias by including patients from several MS centers from widespread cities from Argentina in order to include patients from all possible backgrounds.
The important and novel information provided about the disease-related economic burden is the main contribution of this study to existing literature for MS both in Argentina and the region in terms of costs in a developing country. This information is a valuable tool to make relevant and wise decisions in the field by understanding the exact behavior of the disease in the local setting and supplementary to the use of information from Europe and North America, where resource utilization as well as cost could be rather different from those observed in a developing country like Argentina 4, 9 .
In conclusion, the ENCOMS study provides the Argentine health care system as well as local stakeholders with important information about the economic burden of the disease in our country. Future research performed in our country as well as in other countries of the region, taking in consideration direct and indirect costs of the disease, will expand knowledge and improve management of the disease in the region in terms of this highly relevant issue.
